ArticleDiabetology international2025
Biomarker signatures distinguish diabetic retinopathy and diabetic nephropathy.
Article in Diabetology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cross-Study Meta-Analysis of Blood Transcriptomes in Type 2 Diabetes.International journal of molecular sciences · 2025Pooled it
- Enterococcus hirae Y-HS Alleviates Ulcerative Colitis by Activating PXR/Nrf2-mediated Metabolic-immune Crosstalk.Probiotics and antimicrobial proteins · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to identify distinct sets of genes that can serve as specific biomarkers reflective of biological states distinguishing diabetic nephropathy (DN) or diabetic retinopathy (DR) from healthy individuals, thus providing potential utility for early detection and intervention in diabetic complications. We analyzed two transcriptome datasets (GSE142153 and GSE221521) from the Gene Expression Omnibus, employing the Limma method to identify differentially expressed genes (DEGs) among healthy controls, individuals with DN, and those with DR. Through gene co-regulation mechanisms, we screened for crucial genes related to both DN and DR, and selected candidate biomarkers via functional enrichment analysis, protein-protein interaction network construction, and the integration of machine learning algorithms. Their diagnostic performance was evaluated using receiver operating characteristic curves and dynamic nomogram analysis, and further validated with the GSE154881 and GSE185011 datasets. We identified 48 genes co-regulated by DM and DN, and 171 genes co-regulated by DM and DR. Using protein-protein interaction networks, the top 10 and 18 node genes for DN and DR were screened, respectively, leading to the selection of two biomarkers for DN (HCAR2 and TANK) and three for DR (RHOB, RPL12, and RPS17) through machine learning. Validation results demonstrated the good efficacy of the nomogram, suggesting that these distinct gene sets can serve as specific biomarkers for indicating distinct biological alterations associated with DN and DR. Supplementary Information: The online version contains supplementary material available at 10.1007/s13340-025-00842-w.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.